Since the 1950s, the dietary restriction of the supply of phenylalanine in the diet of phenylketonuria still remains the basic treatment that should be rigorously applied throughout life. The effectiveness of therapy, high during infancy and early childhood, decreases at a later age due to rigor and nuisance. Unfortunately, despite many years of research into phenylketonuria, an effective strategy for the early discovery of discrete brain dysfunction in adolescents and young adults with phenylketonuria, which seems to be necessary, has not yet been developed.The aim of the study was to assess the effect of high levels of phenylalanine in the blood (resulting from inadequate treatment efficacy) on the occurrence of cognitive functions, neuropsychological disorders and emotional disorders in adolescents and young adults with phenylketonuria and clinical usefulness of selected diagnostic methods in early detection of the above disorders.Materials and methods: We analyzed the metabolic profile of a group of 70 patients with phenylketonuria, aged 12-19 years, treated at the Clinic of Metabolic Diseases at the University Children's Hospital in Krakow. For all patients described in works 1, 2 and 3, metabolic profiles were created from the neonatal period to inclusion in the study. The severity and variability of hyperphenylalaninemia was correlated with the assessment of cognitive fu ; nctions (Wechsler's Intelligence Scale), neuropsychological disorders (d2 and Benton tests), emotional (STAI test) and quality of life (General Psychological Well-Being Index) of patients (performed by clinical psychologist).Conclusions: The most useful parameters for both metabolic control in children and predicting the occurrence of brain dysfunction in adolescents with phenylketonuria appear to be the average of mean annual blood phenylalanine levels and the percentage of normal phenylalanine control results. The usefulness of selected diagnostic tools to detect neuropsychological and emotional disorders in adolescents and the quality of life in adult patients with phenylketonuria has also been demonstrated. Obtained results can be used in clinical practice to improve procedures for monitoring the effectiveness of treatment and increasing the safety of patients with phenylketonuria.
pediatria ; genetyka ; psychiatria
Jun 26, 2023
Jul 9, 2019
192
0
http://dl.cm-uj.krakow.pl:8080/publication/4301
Edition name | Date |
---|---|
ZB-129170 | Jun 26, 2023 |
Didycz, Bożena
Kowalska, Katarzyna Olga
Datka, Wojciech
Mączka, Grzegorz
Pastuszak-Draxler, Anna
Epa, Roksana
Przybylska-Just, Joanna
Biegańska-Banaś, Joanna